Business Wire

Circle Pharma Announces Upcoming Presentation at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, a biopharmaceutical company advancing the discovery and development of intrinsically cell-permeable macrocycles, today announced an upcoming poster ...
VentureBeat

Circle Pharma Announces Upcoming Poster Presentation Highlighting the Anti-tumor Potential of Cyclin D1 RxL Inhibition at the AACR-NCI-EORTC International Conference on ...

Cyclin D1 is overexpressed in certain solid tumors and hematologic malignancies. In these cancers, the cyclin D1/CDK4 complex drives cell proliferation by binding to the tumor suppressor ...
Morningstar

Circle Pharma Announces Poster Presentation Highlighting the Potential of CID-078, a First-in-class Oral Cyclin A/B RxL Inhibitor, at the American Association for Cancer ...

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced an upcoming poster presentation highlighting the ...